Novartis, Apotex Resolve Suit Over Myfortic Patents

Law360, New York (August 19, 2011, 5:14 PM EDT) -- Apotex Inc. on Thursday resolved a suit brought in New Jersey federal court by Novartis AG accusing the generics manufacturer of infringing its patents related to the immunosuppressive drug Myfortic.

U.S. District Judge Peter G. Sheridan granted Novartis’ motion to dismiss the case without prejudice, ending litigation that alleged Apotex’s abbreviated new drug application for a generic version of Myfortic infringed three of Novartis’ patents covering the medication.

Terms of the deal to end the case were not disclosed in the order, but the parties told...
To view the full article, register now.